Published in Indoor Air on August 01, 2006
Differential oxidative stress response in young children and the elderly following exposure to PM(2.5). Environ Health Prev Med (2008) 0.82
Estimating mortality derived from indoor exposure to particles of outdoor origin. PLoS One (2015) 0.79
Residential indoor and personal PM10 exposures of ambient origin based on chemical components. J Expo Sci Environ Epidemiol (2014) 0.75
Climate change. Recent reductions in China's greenhouse gas emissions. Science (2001) 5.77
Climate forcing by anthropogenic aerosols. Science (1992) 5.67
Amplification of surface temperature trends and variability in the tropical atmosphere. Science (2005) 2.99
Optimizing the exercise protocol for cardiopulmonary assessment. J Appl Physiol Respir Environ Exerc Physiol (1983) 2.76
Predicted values for clinical exercise testing. Am Rev Respir Dis (1984) 2.58
Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies. J Acquir Immune Defic Syndr (1992) 2.29
Exercise pathophysiology in patients with primary pulmonary hypertension. Circulation (2001) 2.28
Carbon dioxide pressure-concentration relationship in arterial and mixed venous blood during exercise. J Appl Physiol (1985) (2001) 2.26
Diet and flight hypoxemia. Ann Intern Med (1989) 2.02
Effects of obesity on respiratory function. Am Rev Respir Dis (1983) 1.99
Effect of acetazolamide on acute mountain sickness. N Engl J Med (1968) 1.98
O-GLYCBASE version 4.0: a revised database of O-glycosylated proteins. Nucleic Acids Res (1999) 1.81
Prediction of O-glycosylation of mammalian proteins: specificity patterns of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase. Biochem J (1995) 1.81
Greenhouse Effects due to Man-Mad Perturbations of Trace Gases. Science (1976) 1.50
The thyroid function and size in healthy man during 3 weeks treatment with beta-adrenoceptor-antagonists. Horm Metab Res (1991) 1.47
Cardiac output estimated noninvasively from oxygen uptake during exercise. J Appl Physiol (1985) (1997) 1.39
[Treatment of benign recurrent goiter]. Ugeskr Laeger (1994) 1.38
Ethnic differences in pulmonary function in healthy nonsmoking Asian-Americans and European-Americans. Am J Respir Crit Care Med (2000) 1.38
[Episodic hypoxemia and coinciding ECG changes after acute myocardial infarction]. Ugeskr Laeger (1995) 1.37
[False results on elevated triiodothyronine values in radioimmunoassay]. Ugeskr Laeger (1995) 1.37
Forced and unforced ocean temperature changes in Atlantic and Pacific tropical cyclogenesis regions. Proc Natl Acad Sci U S A (2006) 1.36
Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape. J Gen Virol (1993) 1.31
Stoichiometry of monoclonal antibody neutralization of T-cell line-adapted human immunodeficiency virus type 1. J Virol (1999) 1.29
Influence of rifampicin and isoniazid on the kinetics of phenytoin. Br J Clin Pharmacol (1985) 1.29
Relation of oxygen uptake to work rate in normal men and men with circulatory disorders. Am J Cardiol (1987) 1.25
A systematic error in the determination of blood PCO2. Am Rev Respir Dis (1977) 1.21
Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.15
Host cell glycosylation of viral glycoproteins--a battlefield for host defence and viral resistance. Scand J Infect Dis (1998) 1.14
Carbohydrate determinant NeuAc-Gal beta (1-4) of N-linked glycans modulates the antigenic activity of human immunodeficiency virus type 1 glycoprotein gp120. J Gen Virol (1992) 1.13
Identification of an N-linked glycan in the V1-loop of HIV-1 gp120 influencing neutralization by anti-V3 antibodies and soluble CD4. Arch Virol (1994) 1.08
Cardiovascular responses in man during exhaustive work at sea level and high altitude. J Appl Physiol (1967) 1.06
Hyperoxic attenuation of exercise-induced bronchospasm in asthmatics. J Clin Invest (1979) 1.06
A double-blind, randomized clinical trial of methylprednisolone in status asthmaticus. Arch Intern Med (1983) 1.04
Rapid selection for an N-linked oligosaccharide by monoclonal antibodies directed against the V3 loop of human immunodeficiency virus type 1. J Gen Virol (1996) 1.03
Ventilatory and gas exchange kinetics during exercise in chronic airways obstruction. J Appl Physiol Respir Environ Exerc Physiol (1982) 1.01
Development of the optimal inoculation conditions for microcarrier cultures. Biotechnol Bioeng (1992) 1.01
Human air space shapes, sizes, areas, and volumes. J Appl Physiol (1975) 1.00
The typing of Staphylococcus epidermidis by a lectin-binding assay. J Med Microbiol (1992) 1.00
Development and characterization of an antibody directed to an alpha-N-acetyl-D-galactosamine glycosylated MUC2 peptide. Glycoconj J (1998) 0.99
Constructed wetlands treating highway runoff in the central Mediterranean region. Chemosphere (2008) 0.98
Highly active antiretroviral therapy normalizes the function of progenitor cells in human immunodeficiency virus-infected patients. J Infect Dis (1998) 0.98
A noninvasive assessment of pulmonary perfusion abnormality in patients with primary pulmonary hypertension. Chest (2001) 0.98
Antibody to histo-blood group A antigen neutralizes HIV produced by lymphocytes from blood group A donors but not from blood group B or O donors. AIDS (1991) 0.98
Induction of antibodies against epitopes inaccessible on the HIV type 1 envelope oligomer by immunization with recombinant monomeric glycoprotein 120. AIDS Res Hum Retroviruses (1998) 0.97
Immediate effects of cigarette smoking on cardiorespiratory responses to exercise. J Appl Physiol (1985) (1985) 0.97
Pseudocysts of the auricle in Caucasians. Arch Otolaryngol (1967) 0.97
Hearing impairment in orchestral musicians. Scand Audiol (1989) 0.96
Dielectrophoretic forces can be safely used to retain viable cells in perfusion cultures of animal cells. Cytotechnology (1999) 0.96
A novel dielectrophoresis-based device for the selective retention of viable cells in cell culture media. Biotechnol Bioeng (1997) 0.94
Bacterial community dynamics during in-situ bioremediation of petroleum waste sludge in landfarming sites. Biodegradation (2005) 0.93
Branching pattern of airways and air spaces of a single human terminal bronchiole. J Appl Physiol (1975) 0.92
Increased adhesion as a mechanism of antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus infection. J Virol (1995) 0.90
Lung morphometry: a fallacy in the use of the counting principle. J Appl Physiol (1974) 0.89
Breast cancer in systemic lupus erythematosus. Oncology (2013) 0.89
Acute phase reaction, heterogeneity, and microheterogeneity of serum proteins as nonspecific tumor markers in lung cancer. Cancer (1987) 0.89
Response of antidiuretic hormone to acute exposure to mild and severe hypoxia in man. J Endocrinol (1978) 0.89
Safe sorting of GFP-transduced live cells for subsequent culture using a modified FACS vantage. Cytometry (1999) 0.89
Antibody to HIV-1 Tat protein inhibits the replication of virus in culture. Arch Virol (1994) 0.88
Arterial pyruvate, lactate, pH, and PCO2 during work at sea level and high altitude. J Appl Physiol (1967) 0.88
Oxygen uptake in man during exhaustive work at sea level and high altitude. J Appl Physiol (1967) 0.88
Validity of ear oximetry in clinical exercise testing. Chest (1987) 0.87
Quantitative and qualitative binding characteristics of disopyramide in serum from patients with decreased renal and hepatic function. Br J Clin Pharmacol (1987) 0.87
The microheterogeneity of alpha 1-acid glycoprotein in inflammatory lung disease, cancer of the lung and normal health. Clin Chim Acta (1984) 0.87
Thyrotropin receptor antibodies and Graves' disease, a side-effect of 131I treatment in patients with nontoxic goiter. J Clin Endocrinol Metab (1997) 0.86
Clouds of venus: evidence for their nature. Science (1971) 0.86
Diffusing capacity for carbon monoxide as a predictor of gas exchange during exercise. N Engl J Med (1987) 0.86
Abrupt changes in mixed venous blood gas composition after the onset of exercise. J Appl Physiol (1985) (1989) 0.86
Prediction of the secondary structure of HIV-1 gp120. Proteins (1996) 0.86
Monoclonal antibody production in dialyzed continuous suspension culture. Biotechnol Bioeng (1992) 0.86
Intra-arterial and cuff blood pressure responses during incremental cycle ergometry. Med Sci Sports Exerc (1988) 0.85
Application of solvent microextraction to the analysis of nitroaromatic explosives in water samples. J Chromatogr A (2001) 0.85
Comparison of exercise cardiac output by the Fick principle using oxygen and carbon dioxide. Chest (2000) 0.84
Gene therapy of T helper cells in HIV infection: mathematical model of the criteria for clinical effect. Bull Math Biol (1997) 0.84
O-GLYCBASE: a revised database of O-glycosylated proteins. Nucleic Acids Res (1996) 0.84
Expression of the activation antigen CD69 predicts functionality of in vitro expanded peripheral blood mononuclear cells (PBMC) from healthy donors and HIV-infected patients. Clin Exp Immunol (1998) 0.84
The N-linked glycan of the V3 region of HIV-1 gp120 and CXCR4-dependent multiplication of a human immunodeficiency virus type 1 lymphocyte-tropic variant. FEBS Lett (1999) 0.84
Acute appendicitis secondary to metastatic cholangiocarcinoma. Am J Gastroenterol (1993) 0.84
Normal values in adults during exercise testing. Clin Chest Med (1984) 0.84
Comparing treatment intensities of tactile-thermal application. Dysphagia (1998) 0.83
Low-serum medium development for human diploid fibroblast microcarrier cultures. Appl Microbiol Biotechnol (1992) 0.83
Tryptophan fluorescence of yeast actin resolved via conserved mutations. Biophys J (2001) 0.83
Demonstration of peripheral fucose units in N-linked glycans of human immunodeficiency virus type 1 gp 120: effects on glycoprotein conformation. Arch Virol (1997) 0.83
Identification of three N-linked glycans in the V4-V5 region of HIV-1 gp 120, dispensable for CD4-binding and fusion activity of gp 120. Arch Virol (1994) 0.82
Evaluation of autochthonous bioaugmentation and biostimulation during microcosm-simulated oil spills. Mar Pollut Bull (2013) 0.82
Spontaneous silencing of humanized green fluorescent protein (hGFP) gene expression from a retroviral vector by DNA methylation. J Hematother (1998) 0.81
Health and lifestyle characteristics of professional singers and instrumentalists. Occup Med (Lond) (1992) 0.81
Evaluation of the combination effect of different antiviral compounds against HIV in vitro. Scand J Infect Dis (1993) 0.81
Solid-phase microextraction versus single-drop microextraction for the analysis of nitroaromatic explosives in water samples. J Chromatogr A (2001) 0.81
Conserved N-linked oligosaccharides of the C-terminal portion of human immunodeficiency virus type 1 gp120 and viral susceptibility to neutralizing antibodies. Arch Virol (1996) 0.80
Transmission of a minor variant of transcriptionally active HIV-1. Scand J Infect Dis (1999) 0.80
Lung function and exercise performance in smoking and nonsmoking asbestos-exposed workers. Am Rev Respir Dis (1985) 0.80
Complement-mediated enhancement of HIV-1 infection in peripheral blood mononuclear cells. Scand J Infect Dis (1997) 0.80
Kinetic data for the BM-5 insect cell line in repeated-batch suspension cultures. Biotechnol Bioeng (1991) 0.80
Cell cycle model for growth rate and death rate in continuous suspension hybridoma cultures. Biotechnol Bioeng (1992) 0.79
Drug consumption and age in a department of internal medicine. Dan Med Bull (1981) 0.79
Glycosylation of the major human Pneumocystis carinii surface antigen. APMIS (1993) 0.79
Aerobically generated CO(2) stored during early exercise. J Appl Physiol (1985) (1999) 0.79
The HIV-1 V3 domain on field isolates: participation in generation of escape virus in vivo and accessibility to neutralizing antibodies. Arch Virol (1995) 0.79
Effect of endogenous proteins on growth and antibody productivity in hybridoma batch cultures. Cytotechnology (1994) 0.79
Neutralizing antibodies in slowly progressing HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 0.79